| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9144547 | GLAXOSMITHKLINE LLC | Oral dosage form for controlled drug release |
Sep, 2023
(7 months ago) | |
| US8637512 | GLAXOSMITHKLINE LLC | Formulations and method of treatment |
Jun, 2028
(4 years from now) | |
Lamictal Xr is owned by Glaxosmithkline Llc.
Lamictal Xr contains Lamotrigine.
Lamictal Xr has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Lamictal Xr are:
- US9144547
Lamictal Xr was authorised for market use on 29 May, 2009.
Lamictal Xr is available in tablet, extended release;oral dosage forms.
The generics of Lamictal Xr are possible to be released after 14 June, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 29, 2012 |
| New Indication(I-644) | Apr 25, 2014 |
| New Indication(I-622) | Jan 29, 2013 |
| Pediatric Exclusivity(PED) | Nov 29, 2012 |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 29 May, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of LAMICTAL XR before it's drug patent expiration?
More Information on Dosage
LAMICTAL XR family patents
